Patients must not have any history of locally advanced or metastatic cancer requiring systemic therapy within years from randomization, with the exception of in-situ carcinomas and non-melanoma skin cancer; patients must have no previous primary lung cancer diagnosed concurrently or within the past years Prior malignancy within the past years except non-melanoma skin cancer or other localized cancer treated with curative intent Other active malignancy, except non-melanomic skin cancer Diagnosed with or treated for cancer within the previous years, other than breast cancer or non-melanoma carcinoma of the skin. Active, concurrent malignancy requiring radiation, chemotherapy, or immunotherapy (excluding non-melanoma skin cancer, adjuvant hormonal therapy for breast cancer and hormonal treatment for castration sensitive prostate cancer). Diagnosed with or received anti-cancer therapy for another primary malignancy within years prior to entry (except for non-melanoma skin cancer or in situ cancers) Individuals with a history of an active malignancy (other than the current lung cancer diagnosis) within the last years (except non-melanoma skin cancer or a non-invasive/in situ cancer) No history of other cancer (except non-melanoma skin cancer or in situ breast cancer or cervix cancer) unless the tumor was successfully treated with curative intent at least years before trial entry Currently active other malignancy other than non-melanoma skin cancer. Women with previous history of cancer (including invasive or intra-ductal breast cancer) except for non-melanoma skin cancer. EXCLUSION - PROCUREMENT: History of other cancer (except non-melanoma skin cancer or in situ breast cancer or cervix cancer) unless the tumor was successfully treated with curative intent at least years before trial entry Previous or concurrent malignancy other than non-melanoma skin cancer within years of diagnosis of prostate cancer Active, concurrent malignancy requiring radiation, chemotherapy, or immunotherapy (excluding non-melanoma skin cancer, adjuvant hormonal therapy for breast cancer and hormonal treatment for castration sensitive prostate cancer). Known active invasive malignancy except for renal cell carcinoma and/or non-melanoma skin cancer Any concurrent malignancy, except non-melanoma skin cancer Prior malignancy requiring therapy within the last months (excluding non-melanoma skin cancer); hormone therapy for prostate cancer or adjuvant endocrine therapy for breast cancer would not be excluded Other active malignancy within the last years (except for non-melanoma skin cancer, a non-invasive/in situ cancer, or indolent non metastatic Gleason prostate cancer) Active malignancy (with the exception of non-melanoma skin cancer), including relapse or progression of the underlying disease for which qualifying transplant was performed Concomitant active malignancy that would be expected to require chemotherapy within years of transplant (other than non-melanoma skin cancer) Known second primary or prior malignancy diagnosed within years of study start date (other than previously treated non-melanoma skin cancer) Other concurrent cancer (with the exception of non-melanoma skin cancer and low-risk localized prostate cancer on active surveillance) Previous or concurrent history of non-pancreatic malignancy except for non-melanoma skin cancer. Unstable medical condition (e.g., another malignancy requiring treatment, malignant hypertension, poorly controlled diabetes, another cancer except for fully excised non-melanoma skin cancer) Prior malignancy (except non melanoma skin cancer) within years Any known additional malignancy (with exception of non-melanoma skin cancer, in-situ breast cancer or a malignancy diagnosed >= years ago and with no evidence of requiring active treatment) Concurrent malignancy other than non-melanoma skin cancer Active non-hematologic or lymphoid malignancy other than AML treated with immuno- or chemotherapy within the previous months except active non-melanoma, non-invasive skin cancer will be allowed. The subject has no other diagnosis of cancer (unless non-melanoma skin cancer, an early form of cervical cancer, or another cancer diagnosed >= years previously) and currently has no evidence of active other malignancy (unless non-melanoma skin cancer or an early form of cervical cancer) History of malignancy (other than non-melanoma skin cancer) within years of enrollment PROCUREMENT EXCLUSION CRITERA\r\n* Active infection requiring antibiotics\r\n* No history of other cancer (except non-melanoma skin cancer or in situ breast cancer or cervix cancer) unless the tumor was successfully treated with curative intent at least years before trial entry Patients must never have been diagnosed with any malignancy other than the current NSCLC, except for non-metastatic non-melanoma skin cancer, or cancer in situ of the cervix. No history of unrelated (non-lymphomatous) neoplasms within past years other than non-melanoma skin cancer or in-situ cancer Concurrent cancer of any other type except skin cancer (excluding melanoma) Known history of malignancy diagnosed within years other than non-melanoma skin cancer. Previous (within the past years) or concurrent presence of other cancer, except non-melanoma skin cancer and in situ carcinomas. Other active malignancy within the last years (except for non-melanoma skin cancer, a non-invasive/in situ cancer, or indolent nonmetastatic Gleason prostate cancer) They must not have undergone treatment for any other form of cancer (aside from non-melanoma skin cancer) in the past five years Prior or current non-gynecologic or non-breast malignancy within years except non-melanoma skin cancer Known concurrent malignancy (except for non-melanoma skin cancer) Non-melanoma skin cancer; History of non-prostate, primary, malignant cancer, except for non-melanoma skin cancer within previous five years Diagnosed with or treated for cancer within the previous two years, other than breast cancer or non-melanoma carcinoma of the skin No direct evidence of regional or distant metastases after appropriate staging studies; no synchronous primary or prior malignancy in past years except non-melanoma skin cancer or in situ cancer Concurrent untreated cancer excluding non-melanoma skin cancer Have a concurrent active non-breast malignancy except for non-melanoma skin cancer Participants has a prior history of malignancy, with the exception of non-melanoma skin cancer; participants with history of skin cancer must have years elapse since that diagnosis, be in remission, and must not have received chemotherapy, immunotherapy, or radiation therapy Prior malignancy (except non-melanoma skin cancer) within months of study entry NOTE: Patients must be in complete remission from prior malignancy in order to be eligible to enter the study. Patients with an active second malignancy with the exception of non-melanoma skin cancer Concurrent malignancy (other than non-melanoma skin cancer) diagnosed within the past years or any currently active malignancy Prior malignancy (except non-melanoma skin cancer) within years. Patients who have had a history of non-cutaneous malignancy (other than non-melanoma skin cancer) in the previous years are not eligible Active second malignancy other than non-melanoma skin cancer non-melanoma skin cancer Concurrent malignancies other than non-melanoma skin cancer that require active ongoing treatment Malignancy within last years except non-melanoma skin cancer. History of other malignancy within the past years (except non-melanoma skin cancer) Prior malignancy (except non-melanoma skin cancer) within years Malignancy other than nonmelanoma skin cancer Had a malignancy, other than prostate or skin cancer (except malignant melanoma), within years, Patient has a concurrent diagnosis of a another cancer (other than non-melanoma skin cancer) and is in active treatment for it Partner is also diagnosed with cancer (other than non-melanoma skin cancer) and is in active treatment for it Partner cannot have cancer diagnosis (other than non-melanoma skin cancer) and be currently receiving treatment Personal diagnosis of any cancer, other than non-melanoma skin cancer Any other cancer present within the last years (other than gynecologic cancer under study and non-melanoma skin cancer) History of any other malignancy treated within the past years (other than non-melanoma skin cancer) History of any other malignancy treated within the past years (other than non-melanoma skin cancer) No prior history of malignancy other than non-melanoma skin cancer (patient) Prior history of malignancy other than non-melanoma skin cancer (patient) Have a concurrent active non-breast malignancy except for non-melanoma skin cancer Past history of any cancer other than non-melanoma skin cancer Not have been treated for other cancer (except non-melanoma skin cancer) in the past years Participants may have a personal history of non-ovarian malignancy, but must: a) be without evidence of disease at enrollment b) remain premenopausal c) have completed treatment (including surgery, chemotherapy, radiotherapy or hormonal therapy) > months prior to enrollment (other than non-melanoma skin cancer) Women with a history of any cancer within the last years, except for non-melanoma skin cancer; history of breast cancer must be at least > years from diagnosis History of cancer (except for non-melanoma skin cancer) Individuals with any history of cancer other than non-melanoma skin cancer Have received chemotherapy and/or radiation for any malignancy (excluding non-melanoma skin cancer and cancers confined to organs with removal as only treatment) in the past years; ongoing adjuvant hormonal therapy for breast cancer is allowed Evidence of other cancer(s) (excluding non-melanoma skin cancer) within last years Other chronic disease likely to limit lifespan to less than - years, including any cancer requiring treatment in past years except non-melanoma skin cancer New cancer diagnosis in the last six months (with the exception of non-melanoma skin cancer) Subjects with current or previous malignancy other than prostate or non-melanoma skin cancer; Any type of active invasive cancer (excluding breast and non-melanoma skin cancer) within the preceding months Women who have been treated with chemotherapy for prior malignant disease or currently have an untreated malignancy other than non-melanoma skin cancer Diagnosis of any cancer (except non-melanoma skin cancer) With a history of another cancer, except for non-melanoma skin cancer, as per medical records or patient report Prior history of any other malignancy within last years, other than non-melanoma skin carcinoma Concurrent malignancy other than non-melanoma skin cancer Any malignancy other than non-melanoma cell skin cancer, unless no evidence of disease for a minimum of years Patient cannot have received treatment for any malignancy, with the exception of non-melanoma skin cancer, in the past years No prior treatment within years for another cancer, including chemotherapy, surgery (except for diagnostic biopsy), radiation therapy, hormonal therapy or investigational agents, unless curative treatment of non-melanoma skin cancer or in situ cancer Any previous diagnosis of cancer except for non-melanoma skin cancer Patients who have had a history of non-cutaneous malignancy in the previous years are not eligible; exception: patients with history of non-melanoma skin cancer are eligible History of any cancer, other than non-melanoma skin cancer (Arm ) Any malignancy other than non-melanoma cell skin cancer, unless no evidence of disease for a minimum of years